Sponsor Overview
Explore verified public information about EMD Serono's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 1 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 3 supporting sources.
“EMD Serono will consider providing patients with access to an experimental medicine outside of a clinical study in accordance with applicable federal and state laws and regulations using the following 5 principles:”
“EMD Serono will consider providing patients with access to an experimental medicine outside of a clinical study in accordance with applicable laws and regulations using the following principles:”
“If a physician wants to request one of our experimental medicines for a patient with a serious or life-threatening disease or condition the physician should send a request to earlyaccess@emdserono.com. Before doing so, the physician should review our Position Statement on Early Access to Experimental Medicine, download the PDF here, which outlines the principles and criteria we use to evaluate all early access requests.”
Reagan-Udall Foundation Insights
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.